ADAP
Adaptimmune Therapeutics Plc
$1.01
Earnings Summary
Revenue | $0.23Mn |
Net Profits | $-48.33Mn |
Net Profit Margins | -20743.33% |
Highlights
Adaptimmune Therapeutics Plc’s revenue fell -97.89% since last year same period to $0.23Mn in the Q4 2023. On a quarterly growth basis, Adaptimmune Therapeutics Plc has generated -96.82% fall in its revenue since last 3-months.
Adaptimmune Therapeutics Plc’s net profit fell -65.24% since last year same period to $-48.33Mn in the Q4 2023. On a quarterly growth basis, Adaptimmune Therapeutics Plc has generated -5.99% fall in its net profits since last 3-months.
Adaptimmune Therapeutics Plc’s net profit margin fell -7720.77% since last year same period to -20743.33% in the Q4 2023. On a quarterly growth basis, Adaptimmune Therapeutics Plc has generated -3229.32% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Adaptimmune Therapeutics Plc post its latest quarter earnings
EPS Estimate Current Quarter | -0.14 |
EPS Estimate Current Year | -0.14 |
Highlights
Adaptimmune Therapeutics Plc’s earning per share (EPS) estimates for the current quarter stand at -0.14 - a -35.8% fall from last quarter’s estimates.
Adaptimmune Therapeutics Plc’s earning per share (EPS) estimates for the current year stand at -0.14.
Key Ratios
Key ratios of the Adaptimmune Therapeutics Plc post its Q1 2024 earnings
Earning Per Share (EPS) | 0 |
Highlights
Adaptimmune Therapeutics Plc’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2024. This indicates that the Adaptimmune Therapeutics Plc has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-05-06 | -0.14 | 0 | 100% |
₹0 US Stocks a/c Opening Fee